文献速递炎症性肠病消化道肿瘤与早癌

免疫介导疾病患者使用免疫抑制治疗时癌症复发风险:一项更新的系统综述与Meta分析

Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-08-12

该系统综述与Meta分析纳入31项研究、24,328人及85,784人年随访,比较免疫介导疾病且有恶性肿瘤史患者使用不同免疫抑制治疗与未使用免疫抑制者的癌症复发率。结果显示未使用免疫抑制者与各免疫抑制治疗组的癌症复发率相似,乌司奴单抗和维得利珠单抗的癌症发生率数值上较低,未发现JAK抑制剂相关研究。

要点

  • 有恶性肿瘤史的免疫介导疾病患者中,未使用免疫抑制者癌症复发率与使用不同免疫抑制治疗者相似。
  • 乌司奴单抗和维得利珠单抗的癌症发生率数值上较低,但原文未报告统计学比较。
  • 未检索到JAK抑制剂相关研究。

核心结论

  • 在有恶性肿瘤史的免疫介导疾病患者中,未使用免疫抑制者与使用不同免疫抑制治疗者的癌症复发率相似。

研究设计与样本

  • 系统检索PubMed和Embase数据库,纳入31项研究(17项炎症性肠病、14项类风湿关节炎、2项银屑病、1项强直性脊柱炎),共24,328人、85,784人年随访,采用随机效应Meta分析并按治疗类型分层。

主要发现

  • 未使用免疫抑制者:1,627例新发癌症,43,765人年,35/1000人年(95%CI 27-43)。
  • 抗肿瘤坏死因子治疗者:571例新发癌症,17,772人年,32/1000人年(95%CI 25-38)。
  • 免疫调节剂治疗者:1,104例新发癌症,17,018人年,46/1000人年(95%CI 31-61)。
  • 联合免疫抑制治疗者:179例新发癌症,2,659人年,56/1000人年(95%CI 31-81)。
  • 乌司奴单抗:5例新发癌症,213人年,21/1000人年(95%CI 0-44);维得利珠单抗:37例新发癌症,1,951人年,16/1000人年(95%CI 5-26),数值上较低;无JAK抑制剂研究;按免疫抑制启动时机(早期<5年或延迟)分层未显示药物效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There are limited data on the safety of immunosuppressive therapy use in individuals with immune-mediated diseases with a history of malignancy, particularly with newer biologic and small-molecule treatments. METHODS: We performed a systematic search of PubMed and Embase databases to identify studies examining the impact of immunosuppressive therapies on cancer recurrence across several immune-mediated diseases. Studies were pooled together using random-effects meta-analysis and stratified by type of treatment. Primary outcome was occurrence of incident cancers, defined as new or recurrent. RESULTS: Our meta-analysis included 31 studies (17 inflammatory bowel disease, 14 rheumatoid arthritis, 2 psoriasis, and 1 ankylosing spondylitis) contributing 24,328 persons and 85,784 person-years (p-y) of follow-up evaluation. Rates of cancer recurrence were similar among individuals not on immunosuppression (IS) (1627 incident cancers, 43,765 p-y; 35 per 1000 p-y; 95% CI, 27-43), receiving an anti-tumor necrosis factor (571 incident cancers, 17,772 p-y; 32 per 1000 p-y; 95% CI, 25-38), immunomodulators (1104 incident cancers, 17,018 p-y; 46 per 1000 p-y; 95% CI, 31-61), combination immunosuppression (179 incident cancers, 2659 p-y; 56 per 1000 p-y; 95% CI, 31-81). Patients receiving ustekinumab (5 incident cancers, 213 p-y; 21 per 1000 p-y; 95% CI, 0-44) and vedolizumab (37 incident cancers, 1951 p-y; 16 per 1000 p-y; 95% CI, 5-26) had numerically lower rates of cancer. There were no studies on Janus kinase inhibitors. Stratification of studies by timing of immunosuppression initiation did not reveal a medication effect based on early (<5 years) or delayed treatment initiation. CONCLUSIONS: In patients with immune-mediated diseases and a history of malignancy, we observed similar rates of cancer recurrence in those on no immunosuppression compared with different immunosuppressive treatments.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Gupta A, Peyrin-Biroulet L, Ananthakrishnan AN, et al. Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2023. PMID: 37579866. doi:10.1016/j.cgh.2023.07.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。